Abstract
Objective: To evaluate whether dupilumab initiation is associated with reduced short‐term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Study Design: Retrospective cohort study. Setting: TriNetX United States Collaborative Network. Methods: Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab‐treated patients were indexed at treatment initiation and propensity score‐matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios. Results: In 442 matched patients (221 per cohort), dupilumab‐treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20‐0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63‐0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30‐0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab‐treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts. Conclusion: These findings suggest that dupilumab may be a steroid‐sparing and surgery‐sparing option in pediatric CRSwNP.

This publication has 13 references indexed in Scilit: